CCL4-induced Chronic Liver Fibrosis Models in SD Rat

Anti-Tumor Drug Efficacy Evaluation
Humanized Immune Checkpoint Mouse Models and Efficacy Services
Autoimmune Disease Efficacy Evaluation
Autoimmune Nephropathy Models and Efficacy ServicesAsthma Models and Efficacy ServicesSystemic Lupus Erythematosus (SLE) Models and Efficacy ServicesSjögren's Syndrome Models and Efficacy ServicesNeuroimmune Diseases Models and Efficacy ServicesAutoimmune Dermatoses Models and Efficacy ServicesInflammatory Bowel Disease (IBD) Models and Efficacy ServicesRheumatoid Arthritis (RA) Models and Efficacy ServicesImmune Reconstitution Autoimmune Disease Models and Efficacy Services
Metabolic Disease Efficacy Evaluation
Obesity Models and Efficacy ServicesType II Diabetes Models and Efficacy ServiceType I Diabetes Models and Efficacy ServicesAndrogenetic Alopecia (AGA) Models and Efficacy ServicesMASH Models and Efficacy ServicesChronic Liver Fibrosis Models and Efficacy ServicesAcute Liver Injury Models and Efficacy ServicesCholestasis Models and Efficacy ServicesAlcohol-related Liver Disease (ALD) Models and Efficacy ServicesChronic Kindey Disease (CKD) Models and Efficacy ServicesActue Kindey Disease (AKD) Models and Efficacy ServicesDiabetes Nephropathy (Diabetic Kidney Disease) Models and Efficacy ServicesSarcopenia Models and Efficacy ServicesGout/Hyperuricemia Models and Efficacy ServicesFemale Reproduction Models and Efficacy Services
Neurological Disease Efficacy Evaluation
Behavioral AnalysisIn Vivo Drug Efficacy EvaluationDelivering Therapeutics Across the Blood-Brain Barrier (BBB)Parkinson’s Disease Rat Model
Cardiovascular Diseases Efficacy Evaluation
Heart Failure Models and Efficacy ServicesHypertension Models and Efficacy ServicesAtherosclerosis Models and Efficacy ServicesAdvanced Cardiovascular and Metabolic Complication Models and Efficacy ServicesHyperlipidemia Models and Efficacy ServicesHypertropic Cardiomyopathy Models and Efficacy ServicesStroke Models and Efficacy ServicesThrombosis Models and Efficacy Services
Infectious Disease Efficacy Evaluation
About Our Biosafety LaboratoryIn vitro Drug Efficacy EvaluationIn vivo Drug Dfficacy Evaluation
Respiratory Disease Efficacy Evaluation
Acute Lung Injury (ALI) ModelsIdiopathic Pulmonary Fibrosis (IPF) ModelsChronic Obstructive Pulmonary Disease (COPD) ModelsBronchiectasis ModelsPulmonary Function Test
Disease Rat Models
60% HFD Induced DIO Rat ModelsHFHSD+STZ Induced Type II Diabetes Model in SD Rat45％HFHS+STZ Induced Type I Diabetes Models in SD RatCDAHFD-induced Rat MASH ModelCCL4-induced Chronic Liver Fibrosis Models in SD Rat5/6 Nephrectomy-induced Rat CKD ModelAdenine-induced Rat CKD ModelOVX-induced Rat Osteoporosis Model2K1C-induced Hypertension Model in SD RatMCAO-induced CIS Model in SD Rat
Bioanalytical Services
Phenotyping Services
Oncology PlatformMetabolism PlatformEfficacy and Pathology Platform
Non-GLP Toxicity Assessment Services
Cell Therapy & Gene Therapy Efficacy Evaluation

Liver fibrosis is a pathological wound-healing response to chronic liver injury characterized by excessive accumulation of extracellular matrix (ECM) proteins that disrupt normal liver structure. Common causes include viral hepatitis, alcohol abuse, metabolic dysfunction, and toxic impairment. If left untreated, fibrosis may progress to cirrhosis, portal hypertension, and liver failure.


CCL4-induced chronic liver fibrosis models in SD rat

CCl4 generates toxic free radicals via CYP2E1 metabolism, causing lipid peroxidation, necrosis, and activation of hepatic stellate cells (HSCs). The CCl4-induced liver fibrosis model is a gold-standard preclinical system for studying hepatic fibrogenesis, mimicking human progression from hepatocyte injury → inflammation → fibrosis → cirrhosis.


图片1.png

Fig.1 Overview of pharmacodynamic evaluation on CCL4-induced rat chronic liver fibrosis models

 

 图片2.png

Fig.2 Body weight and serum ALT, AST, ALP, TBA and T-BIL of CCL4-induced rat chronic liver fibrosis models


Body weight curve of CCL4-induced rat chronic liver fibrosis models is shown in Fig. 2A. The serum level of ALT, AST, ALP, TBA and T-BIL were significantly higher in CCL4-induced rat chronic liver fibrosis models compared to the control group (Fig. 2B-D). Data were presented by mean ± SEM, N=25-45. *, p < 0.05; **, p < 0.01; ***, p < 0.001 and ****, p < 0.0001

 

图片3.png         

Fig.3 Histological observation of CCL4-induced rat chronic liver fibrosis models


Histopathological staining (HE and Sirius Red) showed significant vacuolar degeneration and fibrous tissue hyperplasia in CCL4-induced rat chronic liver fibrosis models.